01—Abstract
Summary
Summary of the 10-Q filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Guardant Health, Inc. reported a significant increase in revenue for the second quarter and first half of 2025, driven by strong performance in its Oncology and Biopharma and Data segments.
Total revenue for the three months ended June 30, 2025, was $232.1 milliona, up 31% year-over-year, and for the six months ended June 30, 2025, revenue reached $435.6 million, a 26% increase. The company also saw initial revenue from its newly launched Shield screening test. Despite revenue growth, Guardant Health continued to incur net losses, with a loss of $99.9 million for the quarter and $195.1 million for the first half of the year.
The company's cash position remains robust with $735.5 millionb in cash, cash equivalents, and restricted cash as of June 30, 2025, providing ample liquidity for over 12 months. Key developments include the expanding commercial reach of the Shield test, which received National Comprehensive Cancer Network guideline inclusion and met Medicare coverage requirements, alongside continued investment in research and development.
The company also successfully managed its debt structure by completing a note exchange transaction in February 2025, which retired a portion of its 2027 notes and resulted in a gain on extinguishment. Management anticipates continued investment in sales and marketing to drive adoption and expansion, particularly with the Shield product line and international growth initiatives.
02—Key points
Key Highlights
- Total revenue for Q2 2025 increased by 31% to $232.1 million, and by 26% to $435.6 million for the first half of 2025, indicating strong top-line growth.
- The Oncology and Biopharma and Data segments continue to be the primary revenue drivers, showing year-over-year growth of 22% and 28% respectively for Q2 2025.
- Significant progress in the Shield screening test, with initial revenue generated in Q2 2025 and inclusion in NCCN guidelines and Medicare coverage, supporting future growth potential in early cancer detection.
- Despite revenue growth, the company reported net losses of $99.9 million for Q2 2025 and $195.1 million for the first half of 2025, consistent with its growth and investment strategy.
- Guardant Health maintains a strong liquidity position with $735.5 million in cash, cash equivalents, and restricted cash as of June 30, 2025, sufficient for more than 12 months of operations.
- The company completed a note exchange in February 2025, reducing its 2027 convertible notes by $659.3 million and recognizing a $13.7 million gain on extinguishment.
- Operating expenses, particularly sales and marketing, increased substantially (46% for Q2 2025) due to commercial expansion and product launch activities, reflecting ongoing investment in growth.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2025, Guardant Health, Inc. lost $0.43.
- Revenue$232.1M100.0%
- Cost of revenue−$81.2M35.0%
- Gross profit$150.9M65.0%
- Operating costs−$257.3M110.9%
- Operating income−$106.4M45.9%
- Interest, other & tax$6.5M2.8%
- Net income−$99.9M43.0%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 30, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $232.09M$177.24M | +30.9% |
| Cost of Revenue | $81.20M$72.42M | +12.1% |
| Gross Profit | $150.88M$104.81M | +44.0% |
| R&D Expenses | $87.45M$83.10M | +5.2% |
| Operating Expenses | $338.50M$277.85M | +21.8% |
| Operating Income | -$106.41M-$100.62M | −5.8% |
| Interest Expense | $983K$645K | +52.4% |
| Net Income | -$99.90M-$102.63M | +2.7% |
| EPS (Basic) | $-0.80$-0.84 | +4.8% |
| EPS (Diluted) | $-0.80$-0.84 | +4.8% |
| Shares Outstanding (Basic) | 124.11M122.45M | +1.4% |
| Shares Outstanding (Diluted) | 124.11M122.45M | +1.4% |
05—Questions
Frequently Asked Questions
What is the primary driver of Guardant Health's revenue growth in Q2 2025?
Guardant Health's revenue growth in Q2 2025 was primarily driven by increases in test volumes and average selling prices within its Oncology and Biopharma and Data segments. The launch of the Shield screening test also contributed initial revenue.
Despite revenue growth, why is Guardant Health still reporting net losses?
The company is in a growth and investment phase. Significant investments in research and development, expansion of its sales and marketing teams, and clinical studies to support product adoption and payer coverage are contributing to ongoing net losses. These investments are considered crucial for long-term market leadership and revenue generation.
How is Guardant Health managing its debt obligations?
Guardant Health actively manages its debt. In February 2025, it completed a note exchange transaction, exchanging a portion of its 2027 Convertible Senior Notes for 2031 Notes, which reduced its outstanding 2027 notes and resulted in a gain on extinguishment. The company has a substantial cash balance that supports its ongoing operations and debt obligations.
What is the significance of the Shield test's performance and market access?
The Shield test is a key growth driver for Guardant Health in early cancer detection, specifically for colorectal cancer. Its FDA approval, inclusion in NCCN guidelines, and securing Medicare coverage are significant milestones, validating its clinical utility and commercial potential. This is expected to contribute substantially to future revenue.
06—Continue